
    
      The patients will receive infusion of CAR T-cells targeting CD19 and BCMA to confirm the
      safety and efficacy of CD19 and BCMA CAR T-Cells Sequential infusion in acute leukemia with
      alloimmune-mediated platelet transfusion refractoriness.
    
  